Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 9, 2012, Pages 3319-3325

  Norjavaara, Ensio ^a   Ericsson, Hans ^a   Sjob̈erg, Folke ^b   Leonsson Zachrisson, Maria ^a   Sjos̈trand, Mikaela ^a   Morrow, Linda A ^c   Hompesch, Marcus ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c Profil Institute for Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AZD 1656; AZD 6370; C PEPTIDE; ENZYME ACTIVATOR; GLUCAGON; GLUCOKINASE; GLUCOSE; GROWTH HORMONE; HYDROCORTISONE; INSULIN; NEUTRAL INSULIN; NORADRENALIN; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG;

ADRENALIN BLOOD LEVEL; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MALE; MONOTHERAPY; NORADRENALIN BLOOD LEVEL; OPEN STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AZETIDINES; BENZAMIDES; BODY MASS INDEX; C-PEPTIDE; CROSS-OVER STUDIES; ENZYME ACTIVATORS; EPINEPHRINE; GLUCAGON; GLUCOKINASE; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; NOREPINEPHRINE; PYRAZINES; SULFONES; YOUNG ADULT;

EID: 84866164993     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1496     Document Type: Article

References (15)

1. Iynedjian PB 2009 Molecular physiology of mammalian glucokinase. Cell Mol Life Sci 66:27-42
2. Matschinsky FM 2009 Assessing the potential for glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8:399-416
3. Coghlan M, Leighton B 2008 Glucokinase activators in diabetes management. Expert Opin Investig Drugs 17:145-167 (Pubitemid 351578197)
4. Jetton TL, Liang Y, Pettepher CC, Zimmerman EC, Cox FG, Horvath K, Matschinsky FM, Magnuson MA 1994 Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut. J Biol Chem 269:3641-3654 (Pubitemid 24237691)
5. Dunn-Meynell AA, Routh VH, Kang L, Gaspers L, Levin BE 2002 Glucokinase is the most likely mediator of glucosensing in both glucose-excited and glucose-inhibited central neurons. Diabetes 51:2056-2065 (Pubitemid 34729008)
6. Levin BE, Becker TC, Eiki J, Zhang BB, Dunn-Meynall AA 2008 Ventromedial hypothalamic glucokinase is an important mediator of the counterregulatory response to insulin-induced hypoglycaemia. Diabetes 57:1371-1379
7. Kang L, Sanders NM, Dunn-Meynell AA, Gaspers LD, Routh VH, Thomas AP, Levin BE 2008 Prior hypoglycemia enhances glucose responsiveness in some ventromedial hypothalamic glucosensing neurons. Am J Physiol Regul Integr Comp Physiol 294:R784-R792 (Pubitemid 351346954)
8. Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, Kiss I, Durrant J, Cryer P, Gerich J 1991 Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol 260(1 Pt 1):E67-E74
9. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O 2004 Effect of intravenous infusion of exenatide (synthetic extendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycaemia. Diabetes 53:2397-2403 (Pubitemid 39145595)
10. Hallman H, Farnebo LO, Hamberger B, Jonsson G 1978 Asensitive method for the determination of plasma catacholamines using liquid chromatography with electrochemical detection. Life Sci 23:1049-1052
11. Banarer S, McGregor VP, Cryer PE 2002 Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes 51:958-965 (Pubitemid 34438337)
12. Cryer PE, Gerich JE 1983 Relevance of glucose counterregulatory systems to patients with diabetes: critical roles of glucagon and epinephrine. Diabetes Care 6:95-99 (Pubitemid 13144890)
13. Cryer PE 2005 Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes 54:3592-3601 (Pubitemid 43334356)
14. Coope GJ, Atkinson AM, Allott C, McKerrecher D, Johnstone C, Pike KG, Holme PC, Vertigan H, Gill D, Coghlan MP, Leighton B 2006 Predictive blood glucose lowering efficacy by glucokinase activators in high fat fed female Zucker rats. Br J Pharmacol 149:328-335 (Pubitemid 44453434)
15. Bonadonna RC, Heise T, Arbet-Engels C, Kapitza C, Avogaro A, Grimsby J, Zhi J, Grippo JF, Balena R 2010 Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 95:5028-5036